Oncothyreon Inc (ONTY)
-NasdaqGS 1.95 
0.01(0.51%) 2:41PM EDT - Nasdaq Real Time Price
| Prev Close: | 1.96 |
|---|
| Open: | 1.95 |
|---|
| Bid: | 1.94 x 12200 |
|---|
| Ask: | 1.95 x 9100 |
|---|
| 1y Target Est: | 2.80 |
|---|
| Beta: | 1.01 |
|---|
| Next Earnings Date: | 7-Aug-13 |
|---|
| Day's Range: | 1.91 - 1.96 |
|---|
| 52wk Range: | 1.71 - 6.24 |
|---|
| Volume: | 868,306 |
|---|
| Avg Vol (3m): | 865,406 |
|---|
| Market Cap: | 111.57M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.54 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Data on Merck KGaA's L-BLP25Zacks(Wed, May 22)
- What’s Moving These Biotech Stocks?at Motley Fool(Sun, May 19)
- 5 of Last Week's Biggest Losersat Motley Fool(Sun, May 19)
- This Week in Biotechat Motley Fool(Sat, May 18)
- 3 Horrendous Health-Care Stocks This Weekat Motley Fool(Sat, May 18)
- Oncothyreon A Speculative Buyat Seeking Alpha(Fri, May 17)
- ONCOTHYREON INC. FinancialsEDGAR Online Financials(Fri, May 17)
- Merck KGaA Doesn’t Rule Out Pursuing Lung-Cancer Vaccineat Bloomberg(Fri, May 17)
- Cancer Drug Drama Rocks 2 Biotech Stocksat Motley Fool(Thu, May 16)
- Movers roundup: Jack in the Box, OncothyreonAP(Thu, May 16)
- Oncothyreon slumps on new cancer drug dataAP(Thu, May 16)
- Oncothyreon Announces Data for L-BLP25 and PX-866 to be Presented at American Society of Clinical Oncology MeetingPR Newswire(Thu, May 16)
- ASCO '13 Preview: Oncothyreon's Failed Lung Cancer Vaccineat TheStreet(Wed, May 15)
- Oncothyreon Inc Management Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Thu, May 9)
- Oncothyreon Reports First Quarter 2013 Financial ResultsPR Newswire(Thu, May 9)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | N/A |
|---|
| Ex-Dividend Date: | 08-May-95 |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.57 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.15 |
|---|
| Mean Recommendation*: | 2.3 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Oncothyreon Inc, a clinical-stage biopharmaceutical company, engages in the development of therapeutic products for the treatment of cancer. Its lead product candidate is L-BLP25, a vaccine for the treatment of non-small cell lung cancer.
View More